Ingmar Bruns Biography and Net Worth

Chief Medical Officer of Zentalis Pharmaceuticals

Ingmar is Chief Medical Officer of Zentalis. He brings two decades of hematology and oncology experience as a physician and scientist. Prior to joining Zentalis, Ingmar served as Chief Medical Officer of Trillium Therapeutics, a publicly traded clinical stage oncology company, through its acquisition by Pfizer in November 2021, after which he served in clinical development roles at Pfizer, most recently as Development Head, Hematologic Malignancies, Pfizer Global Product Development. Ingmar previously served as the Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, a publicly traded clinical stage biotechnology company, where he built and led the clinical development organization. From 2013 through 2017, he led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Previously, Ingmar served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Ingmar is a board member at Radiant Biotherapeutics, a biotechnology company advancing a proprietary biologics platform designed to treat diseases such as cancer and autoimmune diseases. Ingmar has authored over 50 publications in the field of hematology and oncology, including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

What is Ingmar Bruns' net worth?: The estimated net worth of Ingmar Bruns is at least $140.73 thousand as of February 6th, 2026. Dr. Bruns owns 33,667 shares of Zentalis Pharmaceuticals stock worth more than $140,728 as of May 7th. This net worth approximation does not reflect any other assets that Dr. Bruns may own. Learn More about Ingmar Bruns' net worth.
How do I contact Ingmar Bruns?: The corporate mailing address for Dr. Bruns and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Ingmar Bruns' contact information.
Has Ingmar Bruns been buying or selling shares of Zentalis Pharmaceuticals?: Ingmar Bruns has not been actively trading shares of Zentalis Pharmaceuticals during the last ninety days. Most recently, Ingmar Bruns sold 335 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $2.39, for a transaction totalling $800.65. Following the completion of the sale, the insider now directly owns 33,332 shares of the company's stock, valued at $79,663.48. Learn More on Ingmar Bruns' trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Ingmar Bruns (Chief Medical Officer), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, Zentalis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 6,459,973 shares worth more than $7,751,967.60. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 7,546,617 shares worth more than $10,088,416.65. The most recent insider tranaction occured on February, 10th when insider Vincent Vultaggio sold 6,894 shares worth more than $16,683.48. Insiders at Zentalis Pharmaceuticals own 1.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 2/10/2026.

Ingmar Bruns Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/9/2026	Sell	335	$2.39	$800.65	33,332
2/6/2026	Sell	2,962	$2.43	$7,197.66	33,667
2/6/2025	Buy	20,000	$2.28	$45,600.00	36,629

Ingmar Bruns Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $4.16

$4.11

$4.18

50 Day Range

MA: $3.25

$2.10

$6.61

2 Week Range

Now: $4.16

$1.13

$6.95

Volume

31,761 shs

Average Volume

1,997,524 shs

Market Capitalization

$295.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99